)
Visual
earnings real time
Telix Pharmaceuticals
Telix Pharmaceuticals (TLX) investor relations material
Telix Pharmaceuticals Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary19 Jan, 2026
Executive summary
Achieved FY 2025 unaudited group revenue of US $804M, meeting upgraded guidance and reflecting strong commercial execution, especially in Precision Medicine with the U.S. launch of Gozellix.
Q4 2025 group revenue reached US $208M, up 46% year-over-year, with Precision Medicine revenue at US $161M, up 4% sequentially.
Strategic collaboration announced with Varian to combine radiopharmaceuticals with external beam radiation therapy.
Financial highlights
FY 2025 revenue of US $804M (A$1.2B) aligns with upgraded guidance of US $800â$820M.
Q4 2025 group revenue of US $208M, a 46% increase year-over-year; Precision Medicine revenue of US $161M, up 4% quarter-over-quarter.
RLS third-party revenue was US $45M, down 4% sequentially.
Outlook and guidance
Strong early uptake of Gozellix and integration with ARTMS technology position the business for sustained growth in 2026.
Impact of FDA alignment on Zircaix resubmission
Future scope of Varian collaboration
Strategic impact of TMS global expansion
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- CME
Record revenues, earnings, and volumes in 2025, driven by innovation and global client demand. - SNP
Q4 2025 clean CCS operating result rose 41%, but net income was hit by E&P impairments. - FOXA
Revenue up 2% to $5.18B, net income down, $1.8B in buybacks, strong digital and sports growth. - GAIN
NAV per share climbed to $14.95, led by portfolio gains and strong investment activity. - TROW
AUM up over 10% to $1.78Tâ$1.8T, EPS $9.72, with strong ETF and alternatives growth. - ACB
Record medical cannabis revenue and strategic exits drive margin and profit growth. - BOTX
Record sales, profit, and gold output; investments drive growth and strong 2026 outlook. - NYT
Digital subscriber and ad growth drove record profits, cash flow, and a positive 2026 outlook. - LTM
Record $1.5B net income, 11% revenue growth, and premium expansion drive strong 2026 outlook. - CBT
Adjusted EPS down 13% to $1.53; Battery Materials up 39%; $76M returned to shareholders.
Next Telix Pharmaceuticals earnings date
H2 202519 Feb, 2026
Telix Pharmaceuticals
Next Telix Pharmaceuticals earnings date
H2 202519 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more â with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Telix Pharmaceuticals Limited is a global biopharmaceutical company at the commercial stage, primarily engaged in developing diagnostic and therapeutic products using targeted radiation for cancer and rare diseases. The company is pioneering in the field of radiopharmaceuticals, aiming to advance precision medicine through its innovative approach. Telix's product development focuses on molecularly targeted radiation (MTR) products that seek to improve patient outcomes by precisely targeting diseased cells, thereby minimizing the impact on healthy tissues. Its research pipeline includes a range of diagnostic and therapeutic agents for conditions such as prostate cancer, kidney cancer, glioblastoma (brain cancer), and hematologic cancers, as well as bone marrow conditioning for rare diseases. TThe company is headquartered in North Melbourne, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage